Julia Shaklee Sammons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Julia Shaklee Sammons has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Susan E. Coffin
Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Infection Prevention and Control, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Philadelphia Department of Public Health, Philadelphia, Pennsylvania
4 shared publicationsPhilip Toltzis
Division of Pediatric Critical Care, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
2 shared publicationsSarah A. Smathers
Department of Infection Prevention and Control, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
2 shared publicationsAmanda Shanahan
Department of Inpatient Oncology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
1 shared publicationAna M. Vaughan
Department of Pediatrics, Division of Infectious Diseases, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
1 shared publicationAnne F. Reilly
Department of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- 1 January 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (1) , 137-143
Outbreak of Adenovirus in a Neonatal Intensive Care Unit
- 1 January 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (1) , 137-143
Outbreak of Adenovirus in a Neonatal Intensive Care Unit
- 20 July 2018
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 39 (9) , 1086-1092
Development of a novel prevention bundle for pediatric healthcare-associated viral infections
Objective: To reduce the healthcare-associated viral infection (HAVI) rate to 0.70 infections or fewer per 1,000 patient days by developing and sustaining a comprehensive prevention bundle.Setting: A 546-bed quaternary-care children’s hospital situated in a large urban area.Patients: Inpatients with a confirmed HAVI were included. These HAVIs were identified through routine surveillance by infection preventionists and were confirmed using National Healthcare Safety Network definitions for upper respiratory infections (URIs), pneumonia, and gastroenteritis.Methods: Quality improvement (QI) methods and statistical process control (SPC) analyses were used in a retrospective observational analysis of HAVI data from July 2012 through June 2016.Results: In total, 436 HAVIs were identified during the QI initiative: 63% were URIs, 34% were gastrointestinal infections, and 2.5% were viral pneumonias. The most frequent pathogens were rhinovirus (n=171) and norovirus (n=83). Our SPC analysis of HAVI rate revealed a statistically significant reduction in March 2014 from a monthly average of 0.81 to 0.60 infections per 1,000 patient days. Among HAVIs with event reviews completed, 15% observed contact with a sick primary caregiver and 15% reported contact with a sick visitor. Patient outcomes identified included care escalation (37%), transfer to ICU (11%), and delayed discharge (19%).Conclusions: The iterative development, implementation, and refinement of targeted prevention practices was associated with a significant reduction in pediatric HAVI. These practices were ultimately formalized into a comprehensive prevention bundle and provide an important framework for both patient and systems-level interventions that can be applied year-round and across inpatient areas.
- 20 July 2018
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 39 (9) , 1086-1092
Development of a novel prevention bundle for pediatric healthcare-associated viral infections
Objective: To reduce the healthcare-associated viral infection (HAVI) rate to 0.70 infections or fewer per 1,000 patient days by developing and sustaining a comprehensive prevention bundle.Setting: A 546-bed quaternary-care children’s hospital situated in a large urban area.Patients: Inpatients with a confirmed HAVI were included. These HAVIs were identified through routine surveillance by infection preventionists and were confirmed using National Healthcare Safety Network definitions for upper respiratory infections (URIs), pneumonia, and gastroenteritis.Methods: Quality improvement (QI) methods and statistical process control (SPC) analyses were used in a retrospective observational analysis of HAVI data from July 2012 through June 2016.Results: In total, 436 HAVIs were identified during the QI initiative: 63% were URIs, 34% were gastrointestinal infections, and 2.5% were viral pneumonias. The most frequent pathogens were rhinovirus (n=171) and norovirus (n=83). Our SPC analysis of HAVI rate revealed a statistically significant reduction in March 2014 from a monthly average of 0.81 to 0.60 infections per 1,000 patient days. Among HAVIs with event reviews completed, 15% observed contact with a sick primary caregiver and 15% reported contact with a sick visitor. Patient outcomes identified included care escalation (37%), transfer to ICU (11%), and delayed discharge (19%).Conclusions: The iterative development, implementation, and refinement of targeted prevention practices was associated with a significant reduction in pediatric HAVI. These practices were ultimately formalized into a comprehensive prevention bundle and provide an important framework for both patient and systems-level interventions that can be applied year-round and across inpatient areas.
- 1 June 2017
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 38 (11) , 1385-1387
Mucosal Barrier Injury Central-Line–Associated Bloodstream Infections: What is the Impact of Standard Prevention Bundles?
- 1 June 2017
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 38 (11) , 1385-1387
Mucosal Barrier Injury Central-Line–Associated Bloodstream Infections: What is the Impact of Standard Prevention Bundles?
- 1 September 2015
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 29 (3) , 465-476
Pitfalls in Diagnosis of Pediatric Clostridium difficile Infection
- 1 September 2015
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 29 (3) , 465-476
Pitfalls in Diagnosis of Pediatric Clostridium difficile Infection
- 15 July 2014
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 161 (2) , 145-146
Ready or Not: Responding to Measles in the Postelimination Era
- 15 July 2014
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 161 (2) , 145-146
Ready or Not: Responding to Measles in the Postelimination Era
- 1 June 2013
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 167 (6) , 567-573
Clostridium difficile Infection in Children
Review from JAMA Pediatrics — Clostridium difficile Infection in Children
- 1 June 2013
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 167 (6) , 567-573
Clostridium difficile Infection in Children
Review from JAMA Pediatrics — Clostridium difficile Infection in Children
- Open Access
- 26 March 2013
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (1) , 1-8
Clostridium difficile Infection Is Associated With Increased Risk of Death and Prolonged Hospitalization in Children
Background Clostridium difficile infection (CDI) is associated with significant morbidity and mortality among adults. However, outcomes are poorly defined among children. Methods A retrospective cohort study was performed among hospitalized children at 41 children's hospitals between January 2006 and August 2011. Patients with CDI (exposed) were matched 1:2 to patients without CDI (unexposed) based on the probability of developing CDI (propensity score derived from patient characteristics). Exposed subjects were stratified by C. difficile test date, suggestive of community-onset (CO) versus hospital-onset (HO) CDI. Outcomes were analyzed for matched subjects. Results We identified 5107 exposed and 693 409 unexposed subjects. Median age was 6 years (interquartile range [IQR], 2–13 years) for exposed and 8 years (IQR, 3–14 years) for unexposed subjects. Of these, 4474 exposed were successfully matched to 8821 unexposed by propensity score. In-hospital mortality differed significantly (CDI, 1.43% vs matched unexposed, 0.66%; P < .001). Mortality rates were similar between CO-CDI and matched subjects. However, mortality rates were significantly greater among HO-CDI compared with matched unexposed (odds ratio, 6.73 [95% confidence interval {CI}, 3.77–12.02]). Mean differences in length of stay (LOS) and total cost were significant: 5.55 days (95% CI, 4.54–6.56 days) and $18 900 (95% CI, $15 100–$22 700) for CO-CDI, and 21.60 days (95% CI, 19.29–23.90 days) and $93 600 (95% CI, $80 000–$107 200) for HO-CDI. Conclusions Pediatric CDI is associated with increased mortality, longer LOS, and higher costs. These findings underscore the importance of antibiotic stewardship and infection control programs to prevent this disease in children.
- 26 March 2013
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (1) , 1-8
Open AccessClostridium difficile Infection Is Associated With Increased Risk of Death and Prolonged Hospitalization in Children
Background Clostridium difficile infection (CDI) is associated with significant morbidity and mortality among adults. However, outcomes are poorly defined among children. Methods A retrospective cohort study was performed among hospitalized children at 41 children's hospitals between January 2006 and August 2011. Patients with CDI (exposed) were matched 1:2 to patients without CDI (unexposed) based on the probability of developing CDI (propensity score derived from patient characteristics). Exposed subjects were stratified by C. difficile test date, suggestive of community-onset (CO) versus hospital-onset (HO) CDI. Outcomes were analyzed for matched subjects. Results We identified 5107 exposed and 693 409 unexposed subjects. Median age was 6 years (interquartile range [IQR], 2–13 years) for exposed and 8 years (IQR, 3–14 years) for unexposed subjects. Of these, 4474 exposed were successfully matched to 8821 unexposed by propensity score. In-hospital mortality differed significantly (CDI, 1.43% vs matched unexposed, 0.66%; P < .001). Mortality rates were similar between CO-CDI and matched subjects. However, mortality rates were significantly greater among HO-CDI compared with matched unexposed (odds ratio, 6.73 [95% confidence interval {CI}, 3.77–12.02]). Mean differences in length of stay (LOS) and total cost were significant: 5.55 days (95% CI, 4.54–6.56 days) and $18 900 (95% CI, $15 100–$22 700) for CO-CDI, and 21.60 days (95% CI, 19.29–23.90 days) and $93 600 (95% CI, $80 000–$107 200) for HO-CDI. Conclusions Pediatric CDI is associated with increased mortality, longer LOS, and higher costs. These findings underscore the importance of antibiotic stewardship and infection control programs to prevent this disease in children.